* X4 Pharmaceuticals Inc XFOR.OQ reported a quarterly
adjusted
loss of 7 cents per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -33 cents. The mean expectation of
seven analysts for the quarter was for earnings of one cent per
share. Wall Street expected results to range from -24 cents
to 34 cents per share.
* Revenue was $563.00 thousand; analysts expected $278.67
thousand.
* X4 Pharmaceuticals Inc's reported EPS for the quarter was
45
cents.
* The company reported quarterly net income of $90.83
million.
* X4 Pharmaceuticals Inc shares had risen by 8.8% this
quarter and
lost 24.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for X4
Pharmaceuticals Inc is $5.00
This summary was machine generated from LSEG data August 8 at
01:32 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 0.01 -0.07 Missed
Mar. 31 2024 -0.16 -0.26 Missed
Dec. 31 2023 -0.15 -0.10 Beat
Sep. 30 2023 -0.15 -0.01 Beat